Piper Sandler initiated coverage on shares of LENZ Therapeutics (NASDAQ:LENZ - Free Report) in a research note issued to investors on Monday, MarketBeat reports. The brokerage issued an overweight rating and a $51.00 price target on the stock.
LENZ has been the subject of several other reports. Citigroup boosted their price target on LENZ Therapeutics from $44.00 to $47.00 and gave the company a "buy" rating in a report on Thursday, March 20th. TD Cowen initiated coverage on LENZ Therapeutics in a report on Tuesday, March 18th. They set a "buy" rating and a $60.00 price objective on the stock. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $46.60.
Read Our Latest Analysis on LENZ Therapeutics
LENZ Therapeutics Stock Up 3.3 %
NASDAQ:LENZ traded up $0.76 on Monday, reaching $23.82. The company's stock had a trading volume of 218,555 shares, compared to its average volume of 180,994. The firm has a market cap of $656.07 million, a price-to-earnings ratio of -4.99 and a beta of 0.43. The stock has a 50 day moving average price of $23.49 and a 200 day moving average price of $27.07. LENZ Therapeutics has a 12-month low of $14.42 and a 12-month high of $38.93.
LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last posted its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.04). Equities research analysts expect that LENZ Therapeutics will post -2.18 EPS for the current fiscal year.
Hedge Funds Weigh In On LENZ Therapeutics
A number of large investors have recently made changes to their positions in the company. Harbor Capital Advisors Inc. boosted its holdings in shares of LENZ Therapeutics by 10.5% during the 1st quarter. Harbor Capital Advisors Inc. now owns 48,616 shares of the company's stock valued at $1,250,000 after acquiring an additional 4,627 shares in the last quarter. GAMMA Investing LLC increased its stake in LENZ Therapeutics by 5,254.1% during the 1st quarter. GAMMA Investing LLC now owns 5,836 shares of the company's stock valued at $150,000 after purchasing an additional 5,727 shares in the last quarter. Wellington Management Group LLP increased its holdings in LENZ Therapeutics by 14.6% during the 4th quarter. Wellington Management Group LLP now owns 28,216 shares of the company's stock worth $815,000 after purchasing an additional 3,595 shares in the last quarter. California State Teachers Retirement System lifted its stake in LENZ Therapeutics by 911.0% during the 4th quarter. California State Teachers Retirement System now owns 9,200 shares of the company's stock valued at $266,000 after acquiring an additional 8,290 shares in the last quarter. Finally, Delta Investment Management LLC bought a new stake in LENZ Therapeutics in the 4th quarter worth about $555,000. Institutional investors own 54.32% of the company's stock.
LENZ Therapeutics Company Profile
(
Get Free Report)
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Further Reading
Before you consider LENZ Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.
While LENZ Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
